Taiho's Lonsurf meets OS endpoint in Phase III for gastric cancer

Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) and partner Servier (Suresnes, France) said Lonsurf trifluridine/tipiracil as third-line treatment met the primary endpoint of improving overall

Read the full 241 word article

User Sign In